Related Experiment Videos
[Extrapyramidal signs in Alzheimer's disease]
A Pfeffer-Baczuk1, M Barcikowska, A Karwańska
1Zakładu Neuropatologii, Centrum Medycyny Doświadczalnej i Klinicznej PAN w Warszawie.
Neurologia I Neurochirurgia Polska
|May 1, 1996
Summary
Extrapyramidal signs, like bradykinesia and rigidity, are common in Alzheimer's disease patients. Their presence is linked to more severe dementia but not other disease characteristics.
Area of Science:
- Neurology
- Geriatrics
- Neuroscience
Background:
- Alzheimer's disease (AD) is a progressive neurodegenerative disorder.
- Extrapyramidal signs (EPS) are motor symptoms typically associated with other neurological conditions.
- The prevalence and impact of EPS in AD are not fully understood.
Purpose of the Study:
- To investigate the occurrence of extrapyramidal signs in patients diagnosed with probable Alzheimer's disease.
- To identify common EPS features in this population.
- To explore the relationship between EPS and clinical characteristics of Alzheimer's disease, including dementia severity.
Main Methods:
- Assessed 112 patients meeting NINCDS/ADRDA criteria for probable Alzheimer's disease.
- Evaluated patients for the presence and type of extrapyramidal signs.
- Compared clinical features, including age of onset, symptom duration, primitive reflexes, psychotic symptoms, and dementia severity, between patients with and without EPS.
Main Results:
- Extrapyramidal signs were observed in 50% of the Alzheimer's disease patients.
- Bradykinesia and rigidity were the most frequent EPS observed.
- Resting tremor was rare.
- No significant differences in age of onset, symptom duration, primitive reflexes, or psychotic symptoms were found between groups.
- EPS presence was significantly associated with greater dementia severity.
Conclusions:
- Extrapyramidal signs are a common feature in a significant portion of Alzheimer's disease patients.
- Bradykinesia and rigidity are the predominant EPS in this cohort.
- The presence of EPS in Alzheimer's disease is a marker of increased dementia severity, suggesting a potential link to disease progression or specific pathological subtypes.